Geron reports 17 percent revenue growth: Geron stock has a USD 4.25 target

Published on 10/08/2026 at 21:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron guides to USD 220.00-240.00 million for RYTELO in 2026. Geron stock costs EUR 1.07 on October 8, 2026 after EUR 1.08, down 0.93 percent.

Key points in brief

Geron reported second-quarter 2026 revenue growth of 17.00 percent to USD 57.50 million.
Management expects 2026 RYTELO revenue of USD 220.00-240.00 million and operating expenses of USD 230.00-240.00 million.
Geron stock was trading at EUR 1.07 at Lang & Schwarz on October 8, 2026, down 0.93 percent versus EUR 1.08.
The Nasdaq-listed biotechnology company had a market capitalization of USD 769.8 million as of October 8, 2026.

GERN, US3741631036, Illustration mit AI erstellt.

Geron (ISIN US3741631036) was trading at EUR 1.07 at Lang & Schwarz on October 8, 2026 at 8:59 p.m. CEST, down 0.93 percent versus the prior close of EUR 1.08. In its second-quarter earnings call, Benzinga reported on October 8, 2026 that revenue rose 17.00 percent year over year to USD 57.50 million, while Stockanalysis listed an average USD 4.25 price target from five analysts.

Three milestones with figures

On August 5, 2026, Geron reported second-quarter revenue of USD 57.48 million, compared with a USD 55.30 million consensus estimate, according to MarketBeat. On September 16, 2026, MarketBeat reported that management expected RYTELO revenue toward the upper part of its USD 220.00-240.00 million 2026 guidance range. On October 8, 2026, the earnings call put second-quarter revenue at USD 57.50 million and said first-half revenue increased 24.00 percent year over year, according to Benzinga.

What does growth mean for cash?

The commercial progress is paired with continued spending. Geron said cash, cash equivalents, restricted cash and marketable securities totaled USD 327.00 million at the end of the second quarter, while full-year operating expense guidance remained USD 230.00-240.00 million, according to Benzinga. The key operating comparison is clear: first-half revenue grew 24.00 percent while first-half operating expenses declined 4.00 percent year over year.

Geron is also balancing commercial execution against clinical risk. The company said its 327-patient Phase 3 IMpactMF study remains on its projected timeline, with final overall survival analysis planned for the second half of 2028, according to the October 8, 2026 transcript. That long timetable leaves RYTELO sales as the nearer-term financial driver.

Next reporting date

Stockanalysis lists November 4, 2026 as the estimated date for Geron's next earnings report.

Stock trades below its yearly high

Geron stock was trading at EUR 1.07 at Lang & Schwarz on October 8, 2026 at 8:59 p.m. CEST, down 0.93 percent versus the prior close of EUR 1.08. The primary Nasdaq quote was USD 1.20 at 3:00 p.m. ET on October 8, 2026, while the USD 1.04 to USD 2.01 52-week range places the US-listed price near its yearly low. The further course of trading is shown by the continuously updated real-time quote of Geron stock.